Metabolic, Circadian trading halted ahead of trial results

By Staff Writers
Thursday, 09 December, 2004

Trading in shares of Metabolic Pharmaceuticals (ASX:MBP) and Circadian Technologies (ASX:CIR) was halted today, in advance of the release of data from Phase IIb trials of Metabolic's obesity drug, AOD9604.

Circadian is Metabolic's largest shareholder, owning 21 per cent of shares.

Personalised melanoma vaccine cuts risk of recurrence

Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...

Research project to produce fish-free omega-3

SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...

Biodegradable smart patch can detect and treat blood clots

Researchers have developed a biodegradable smart patch that detects pressure changes and releases...

Content from other channels on our network

Novel method to reduce metal waste in manufacturing

ARENA backs hydrogen technology for steelmaking pilot

CSIRO suggests ways Australia can grow battery manufacturing sector

MathWorks certified to provide guidance for AI‍-‍assisted engineering

NSW opens expressions of interest for Bradfield enterprise precinct

Smart bedding targets falls risk in aged care

Calvary confirms some services across two hospitals "will not be offered"

Opinion: Beyond connectivity — making health data meaningful across systems

Winning healthcare equipment tenders: why having the best product is no longer enough

Optimising connectivity: Peninsula University Hospital

Tiny chip may cut AI's growing energy demands

Registrations now open for Clean Up Australia Day 2027

Tilt Renewables awarded five-star rating

"Solar tsunami" may hit businesses as installers go broke

Tiny molecule 'superhighways' to improve industrial processing